ASCO Round-Up: Chronix Delta Dots, HTG EdgeSeq, and Guardant360 Liquid Biopsy
This article was originally published in Clinica
The annual American Society of Clinical Oncology (ASCO) conference June 3-7 in Chicago was dominated by drug trials, but also included many presentations on new diagnostic technologies.
You may also be interested in...
Liquid biopsies – carrying out diagnostic tests on liquid samples such as blood or urine rather than on tissue biopsy material – look set to revolutionize the management of cancer patients. This area has recently captured the interest of a growing number of diagnostic players, both big and small, and spawned the development of different approaches to liquid biopsy. This article marks out who's who in this increasingly busy landscape and the key technologies that are showing promise, and looks at the obstacles that companies are facing.
CMR Surgical will collaborate with Johnson & Johnson/Ethicon to expand access to its Versius robotic surgery system.
Medtech Insight followed-up with Cordis CEO Shar Matin to talk about the company’s path forward as an innovative intervention company following the acquisition of MedAlliance.